On November 12, 2013 Xiamen Innovax Biotech Co. Ltd. got CFDA approvals for Bivalent Human Papillomavirus (Type 6/11) Recombinant Vaccine (No.2013L0372) for clinical trials of phase I, II, III. The vaccine is mainly used for Genital warts prevention. In China, the statistics indicated at least 80% of Genital warts caused by human papillomavirus.
